1. HBW Insight
  2. >>Health
  3. >>Business
  4. >>Earnings

European OTC Results Round-Up: Boiron, Alliance Pharma and Karo

 
• By Tom Gallen

COVID-19 had a differing impact on Q2 consumer health sales for France's Boiron, the UK's Alliance Pharma and Sweden's Karo.

Quarterly resluts on typewriter close up
• Source: Shutterstock

French homeopathy specialist Boiron blamed the impact of the global coronavirus pandemic, plus ongoing troubles in its domestic market, as it posted second-quarter sales down by 14.5% at constant exchange rates to €97m ($111m).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

‘The Only Certainty Is Uncertainty’ In The UK’s Consumer Health Market

 
• By David Ridley

While uncertainty might reign in the UK consumer health market - which grew by by 8% to £4.1bn ($5.3bn) in 2024 - “opportunity is everywhere” according to NielsenIQ health and beauty insights manager Alex Heffernan.

France’s Boiron Looks To Future After Challenging Year

 
• By Tom Gallen

The homeopathy specialist reported a big decline in profits in 2024 as a move to restructure its ailing French operation hit the bottom line.

Reducing Complexity Helps Weleda Break Sales Record

 
• By Tom Gallen

Swiss firm reports highest revenues in its history as restructure pays off for its pharma and cosmetics businesses in 2024.

End Of Year Recovery Ensures Recordati’s OTC Business Keeps Growing

 
• By Tom Gallen

Jump in cough & cold sales at the end of the year helps Recordati post higher OTC revenues for 2024.

More from Business

KKR Expands Health & Beauty Portfolio With Deal For Sweden’s Karo

 
• By Tom Gallen

Consumer health player Karo is changing hands from EQT to KKR in a deal thought to value the Stockholm-based firm at over €2.5bn.

‘The Only Certainty Is Uncertainty’ In The UK’s Consumer Health Market

 
• By David Ridley

While uncertainty might reign in the UK consumer health market - which grew by by 8% to £4.1bn ($5.3bn) in 2024 - “opportunity is everywhere” according to NielsenIQ health and beauty insights manager Alex Heffernan.

France’s Boiron Looks To Future After Challenging Year

 
• By Tom Gallen

The homeopathy specialist reported a big decline in profits in 2024 as a move to restructure its ailing French operation hit the bottom line.